S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

$3.10
+0.86 (+38.39%)
(As of 04/16/2024 ET)
Today's Range
$2.11
$3.37
50-Day Range
$2.08
$3.42
52-Week Range
$1.86
$16.74
Volume
703,480 shs
Average Volume
27,062 shs
Market Capitalization
$4.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Finch Therapeutics Group MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Finch Therapeutics Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$17,070 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

FNCH stock logo

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

FNCH Stock Price History

FNCH Stock News Headlines

Finch Therapeutics Group (NASDAQ: FNCH)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Finch Therapeutics Group Inc (FNCH)
Finch Therapeutics Group Inc FNCH
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
8-K: Finch Therapeutics Group, Inc.
FINCH THERAPEUTICS GROUP INC
Finch Therapeutics Group (FNCH) Gets a Buy from H.C. Wainwright
See More Headlines
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/25/2024
Today
4/16/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FNCH
Fax
N/A
Employees
18
Year Founded
N/A

Profitability

Net Income
$-74,750,000.00
Pretax Margin
-73,098.12%

Debt

Sales & Book Value

Annual Sales
$110,000.00
Book Value
$14.25 per share

Miscellaneous

Free Float
885,000
Market Cap
$3.69 million
Optionable
No Data
Beta
0.46
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

FNCH Stock Analysis - Frequently Asked Questions

How have FNCH shares performed in 2024?

Finch Therapeutics Group's stock was trading at $3.61 at the beginning of 2024. Since then, FNCH stock has decreased by 14.1% and is now trading at $3.10.
View the best growth stocks for 2024 here
.

Are investors shorting Finch Therapeutics Group?

Finch Therapeutics Group saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 9,200 shares, a decrease of 20.7% from the March 15th total of 11,600 shares. Based on an average daily trading volume, of 17,700 shares, the short-interest ratio is presently 0.5 days. Approximately 1.7% of the company's stock are sold short.
View Finch Therapeutics Group's Short Interest
.

When is Finch Therapeutics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FNCH earnings forecast
.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its earnings results on Monday, March, 25th. The company reported ($1.89) earnings per share (EPS) for the quarter.

When did Finch Therapeutics Group's stock split?

Finch Therapeutics Group shares reverse split on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FNCH) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners